The efficacy data reported in this real-life study with unselected patients were close to outcomes from the two phase II studies which demonstrated the clinical efficacy of dabrafenib plus trametinib in patients with stage IV BRAF V600E-mutant NSCLC. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.